Britain snubs costly Novartis blood cancer drug
British health authorities said on Wednesday they would not recommend Jakavi, a drug produced by Swiss pharmaceutical company Novartis to treat a rare form of blood cancer, deeming it too expensive.
Jakavi, or Ruxolitinib, was "clinically effective but could not be considered a cost-effective use of (the National Health Services') resources," the National Institute for Health and Clinical Excellence (NICE) said in a statement.
While NICE concluded that Ruxolitinib effectively treated symptoms and "could offer survival benefit," it lamented that it was simply too expensive to impose on the public health system, since it would mean diverting costs from elsewhere.
"It is disappointing not to be able to recommend this new treatment in our preliminary recommendations," it said.
Novartis, which is facing a wave of expiring patents on its traditional big-sellers, is working hard to multiply its new drug offerings like Javaki to ensure continued growth.
But like the rest of the pharmaceutical industry, the company has also had to deal with growing pricing pressure at a time when crisis-hit countries are increasingly being forced to slash health expenditures.
Last month it announced that its net sales in 2012 had slipped 3.0 percent year-on-year to $56.7 billion (42.1 million euros).
(c) 2013 AFP
- EU approves Novartis-Incyte blood cancer drug Sep 04, 2012 | not rated yet | 0
- Novartis says EU approves expanded use of Glivec Feb 27, 2012 | not rated yet | 0
- EU approves Novartis drug Signifor for Cushing's disease Apr 25, 2012 | not rated yet | 0
- NGOs protest Novartis' Glivec patent quest in India Feb 23, 2012 | not rated yet | 0
- Novartis insists its flu vaccines are safe Oct 25, 2012 | not rated yet | 0
- Motion perception revisited: High Phi effect challenges established motion perception assumptions Apr 23, 2013 | 3 / 5 (2) | 2
- Anything you can do I can do better: Neuromolecular foundations of the superiority illusion (Update) Apr 02, 2013 | 4.5 / 5 (11) | 5
- The visual system as economist: Neural resource allocation in visual adaptation Mar 30, 2013 | 5 / 5 (2) | 9
- Separate lives: Neuronal and organismal lifespans decoupled Mar 27, 2013 | 4.9 / 5 (8) | 0
- Sizing things up: The evolutionary neurobiology of scale invariance Feb 28, 2013 | 4.8 / 5 (10) | 14
How can there be a term called "intestinal metaplasia" of stomach
19 hours ago Hello everyone, Ok Stomach's normal epithelium is simple columnar, now in intestinal type of adenocarcinoma of stomach it undergoes "intestinal...
Pressure-volume curve: Elastic Recoil Pressure don't make sense
May 18, 2013 From pressure-volume curve of the lung and chest wall (attached photo), I don't understand why would the elastic recoil pressure of the lung is...
If you became brain-dead, would you want them to pull the plug?
May 17, 2013 I'd want the rest of me to stay alive. Sure it's a lousy way to live but it beats being all-the-way dead. Maybe if I make it 20 years they'll...
MRI bill question
May 15, 2013 Dear PFers, The hospital gave us a $12k bill for one MRI (head with contrast). The people I talked to at the hospital tell me that they do not...
Ratio of Hydrogen of Oxygen in Dessicated Animal Protein
May 13, 2013 As an experiment, for the past few months I've been consuming at least one portion of Jell-O or unflavored Knox gelatin per day. I'm 64, in very...
Alcohol and acetaminophen
May 13, 2013 Edit: sorry for the typo in the title , can't edit I looked around on google quite a bit and it's very hard to find precise information on the...
- More from Physics Forums - Medical Sciences
More news stories
An experimental sleeping pill from US drug company Merck is effective at helping people fall and stay asleep, according to reviewers at the US Food and Drug Administration, which could soon approve the new drug.
Medications 8 hours ago | 3 / 5 (2) | 0
Transparent information on the evidence supporting global recommendations on paediatric medicines should be easily accessible in order to help policy makers decides on what drugs to include in their national drug lists, according ...
Medications 9 hours ago | not rated yet | 0
Regardless of pain, social class or age, a woman is more likely to be prescribed pain-relieving drugs. A study published in Gaceta Sanitaria (Spanish health scientific journal) affirms that this phenomenon is inf ...
Medications 17 hours ago | not rated yet | 0
A new report suggests that improved health care and significant reductions in drug costs might be attained by breaking up the age-old relationship between physicians and drug company representatives who promote the newest, ...
Medications May 20, 2013 | 5 / 5 (1) | 0
(Medical Xpress)—Native peoples in regions where cameras are uncommon sometimes react with caution when their picture is taken. The fear that something must have been stolen from them to create the photo ...
14 hours ago | 4.2 / 5 (5) | 0 |
(Medical Xpress)—Despite spending billions of dollars on research and development, drug companies have been unable to come up with effective treatments for dementia and Alzheimer's Disease (AD). Now, A. ...
12 hours ago | 4.9 / 5 (11) | 0 |
Australian scientists have charted the path of insulin action in cells in precise detail like never before. This provides a comprehensive blueprint for understanding what goes wrong in diabetes.
14 hours ago | 4.6 / 5 (7) | 0 |
Activating an enzyme known to play a role in the anti-aging benefits of calorie restriction delays the loss of brain cells and preserves cognitive function in mice, according to a study published in the May ...
9 hours ago | 5 / 5 (4) | 0 |
A drug commonly used to treat depression and anxiety may improve a stress-related heart condition in people with stable coronary heart disease, according to researchers at Duke Medicine.
10 hours ago | 5 / 5 (1) | 0 |
Researchers at USC have found that a class of pharmaceuticals can both prevent and treat Alzheimer's Disease in mice.
11 hours ago | 5 / 5 (6) | 0 |